Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer

Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
September 25, 2023 19:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
September 21, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
September 12, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
September 06, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
September 01, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
August 17, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
August 09, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoingNXP900 IND cleared by the US FDA, start of Phase 1a study expected in Q3 2023 ...
June 20, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes

Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
May 15, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...